vTv Therapeutics Inc.
VTVT
$35.08
-$1.74-4.73%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 129.73% | -44.33% | |||
| Gross Profit | 812.92% | 44.33% | |||
| SG&A Expenses | 15.61% | 8.10% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 72.18% | -26.30% | |||
| Operating Income | 395.03% | 26.30% | |||
| Income Before Tax | 438.11% | 31.00% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 438.11% | 31.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -100.00% | |||
| Net Income | 438.11% | 17.94% | |||
| EBIT | 395.03% | 26.30% | |||
| EBITDA | 395.12% | 26.31% | |||
| EPS Basic | 438.11% | 46.73% | |||
| Normalized Basic EPS | 438.11% | 39.89% | |||
| EPS Diluted | 386.86% | 46.73% | |||
| Normalized Diluted EPS | 386.70% | 39.89% | |||
| Average Basic Shares Outstanding | 0.00% | 54.03% | |||
| Average Diluted Shares Outstanding | 17.94% | 54.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||